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1. Introduction 
In order to secure the continued supply of oxygen to the tissues, the integrity of the vascular 
system is of prime importance for survival. Several systems therefore exist that safeguard 
the circulatory system and that include emergency- and repair systems. As a protective 
system, primary haemostasis and blood coagulation function in concert in order to prevent 
extensive loss of blood from the organism in the event of vascular damage (Dahlbäck, 2000). 
Not only humoral and cellular factors limit the loss of blood, a first-line-of-defense is formed 
by the physiological process of vasoconstriction which is initiated upon a breach of vascular 
integrity. 
Being capable of converting the fluid-like medium blood into a gel-like blood clot within a 
very short span of time implies that the haemostatic system incorporates the intrinsic 
dangerous capacity of damaging the very system it is intended to protect. This is the reason 
why the haemostatic system is subject to strict regulation by several anticoagulant 
mechanisms, which together prevent the excessive or inappropriate deposition of blood 
clots within the vascular system.  
Rather than being a dormant system that only responds to changes in the vasculature, it is 
generally accepted that the haemostatic response, as it occurs in healthy individuals, is 
instead the result of the upregulation of ongoing coagulation reactions. Under normal 
conditions, these coagulation reactions, as well as anticoagulation reactions proceed 
continuously at a low level and pro- and anticoagulant reactions balance each other in a 
dynamic equilibrium. The temporal upregulation of only procoagulant reactions will shift 
the balance to favor a procoagulant response, (Dahlbäck & Stenflo, 1994). 
The maintenance of both pro- and anticoagulant reactions at a low but vigilant level, ensures 
that the haemostatic system is able to generate a swift response when needed, which can be 
achieved through  up-regulation of either the pro- or anticoagulant processes. The initiation 
of procoagulant processes implicitly instigates the initiation of anticoagulation responses, as 
will be detailed below, by the activation of the proteolytic protein C anticoagulant pathway. 
The coupling of pro-and anticoagulant responses is of vital importance since whenever 
procoagulant reactions are not controlled by anticoagulant mechanisms, or when 
anticoagulant processes are defective, the formation of thrombin will become excessive and 
the risk for thrombosis will increase.  
Despite considerable progress in their diagnosis and treatment, ischemic heart disease and 
cerebrovascular disease, remain to be the major cause of mortality worldwide, with over 
80% of cardiovascular disease deaths now taking place in low-and middle-income countries 
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and occurring almost equally in men and women (Global Health Observatory (GHO), 
World Health Organisation [WHO], 2008).  
Thromboembolic disease contributes to this overall mortality, as it is  implicated in many 
manifestations of cardiovascular disease. The clinical manifestation of a thrombus is that of 
the pathological presence of an occlusion in a blood vessel or in the heart, which causes an 
obstruction of the physiological flow of blood through the circulatory system. Such 
occlusions can occur in either the venous or arterial part of the vessel tree and the condition 
is consequently classified as either venous or arterial thrombosis. Despite the fact that in 
both venous and arterial thrombosis the normal haemostatic balance is disturbed, the two 
types of thrombosis are considered distinct disease states that each have their own particular 
molecular pathology and underlying risk factors (Rosendaal, 1999, 2005). 
The proper functioning of the anticoagulant protein C pathway is undisputedly required to 
prevent the occurrence of thrombosis, and in particular venous thromboses, as is most 
strikingly illustrated for protein C deficiency. Newborns who are homozygous protein C 
deficient can develop the life-threatening condition of acute onset “purpura fulminans” 
(Dreyfus et al, 1991, 1995) which can be treated by replacement therapy employing purified 
protein C concentrates. 
Resistance to activated protein C (APC), or APC resistance, the subject of this chapter, has 
been implicated mostly in pathogenesis of venous thrombosis, despite the fact that the 
causative FVLeiden mutation, which is present in a majority of cases, has been related to 
myocardial infarction and/or overall coronary disease (Rallidis et al.2003; Segev et al., 2005; 
Ye et al., 2006). Various clinical studies have been performed to identify the contribution of 
the anticoagulant protein C pathway to arterial thromboses and stroke and these have not 
been conclusive in providing clear evidence for the contribution of the protein C pathway to 
arterial thrombosis (e.g. Folsom, 1999; Hankey, 2001; Boekholdt, 2007). That there is a link 
between the hemostatic system and arterial thrombosis or atherosclerosis appears clear as it 
has been established that many complex diseases, such as atherosclerosis, show an extensive 
crosstalk between inflammation and coagulation, as was recently reviewed by Borisoff and 
coworkers (Borisoff et al, 2011). 
Venous thrombosis (or venous thromboembolism, VTE) is a multifactorial disease 
(Seligsohn&Zivelin, 1997; Rosendaal, 1999) that affects one in 10,000 individuals under the 
age of 40 years annually and one in 1,000 individuals over 75 years of age, causing 
significant morbidity and mortality (Salzman &  Hirsh, 1994;  Anderson et al., 1991; 
Nordstrom et al. 1992). The multifactorial character of VTE implies that for the disease to 
occur often several circumstantial and genetic factors occur simultaneously. Together these 
factors are capable of tipping the natural haemostatic balance between pro- and 
anticoagulant forces. Important to note is that environmental and acquired factors are able 
to modulate the existing genetic risk factors for thrombosis in an individual and these 
acquired factors, which may be very diverse by nature, are consequently directly involved 
in the pathogenesis of thrombosis. Thrombosis will develop then when the combined risk 
factors interact such that the threshold for thrombosis is surpassed. Upon passing of the 
threshold, the anticoagulant mechanisms are no longer able to counteract the procoagulant 
forces. Consequently a thrombotic event can occur (Rosendaal, 1999). 
Of the inherited risk factors for venous thrombotic disease, most are found in the protein C 
anticoagulant system which will be detailed below. Examples of these are resistance to 
activated protein C (APC) caused by the FVLeiden mutation (FV R506Q) and the deficiencies 
of the cofactor, protein S, and deficiency of protein C itself (Segers et al., 2007). Of the 
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acquired risk factors, use of oral contraceptives, pregnancy/puerperium, the presence of 
antiphospholipid antibodies, immobilization, surgery, malignancies and trauma are 
amongst the most studied. Furthermore, age and sex are recognized as independent 
contributing factors in the pathogenesis of venous thrombosis (Bertina, 2001). 
In this chapter resistance to APC, the central protein of the protein C anticoagulant pathway, 
will be discussed, both for genetically determined forms of APC resistance and acquired 
types of APC resistance. Particular attention will be given to the molecular events that occur 
during the APC-catalyzed down-regulation of thrombin formation in normal individuals, 
since knowledge of these processes is pivotal in our understanding of the causative role of  
APC resistance in the occurrence of thromboembolic disease.  
2. Protein C anticoagulant pathway 
During homeostasis several anticoagulant systems balance the procoagulant forces that act 
in human blood, thereby preventing excessive platelet and fibrin depositions. A major 
inhibitory buffer is formed by the circulating inhibitors, which include antithrombin, alpha-
2-macroglobulin, antitrypsin or tissue factor pathway inhibitor (TFPI) which provide the 
necessary negative feedback to procoagulant forces. These circulating inhibitors target the 
activated forms of the serine proteases from the coagulation cascade like thrombin and FXa 
and act by complex formation with their target proteases, resulting in a loss of proteolytic 
activity and clearance of the active protease from circulation. 
Key regulators in the amplification of thrombin formation are however the non-enzymatic 
cofactor proteins factor V (FV) and factor VIII (FVIII) and by virtue of the absolute 
requirement of their activity for normal thrombogenesis, they are obvious targets for the 
attenuation of thrombin formation. Given that these molecules lack proteolytic activity, they 
cannot be inactivated via complex formation but instead they are targeted by proteolytic 
inactivation, resulting in disintegration of the protein structure and concomittant loss of 
cofactor activity. The main proteolytic enzyme responsible for the inactivation of activated 
FV (FVa) and FVIII (FVIIIa) is the activated form of protein C. 
Low levels of activated protein C circulate, but for a sufficient anticoagulant response to 
occur, an upregulation of protein C is required through a specific set of molecular events, 
which together are described as the protein C anticoagulant pathway. The main player in 
this pathway is protein C. Protein C is a vitamin K dependent zymogen belonging to the 
class of chymotrypsin-like serine proteases (Stenflo, 1976). Being a zymogen, protein C 
circulates at a plasma concentration of ~65 nM in humans as an inactive pro-enzyme which 
requires processing in order to obtain its enzymatic activity. A pivotal role in the initiation 
of the protein C pathway is the formation of a complex between thrombin and 
thrombomodulin (Fuentes-Prior et al, 2000), see Fig. 1 below. Note that it is thrombin, the 
very enzyme that ultimately needs to be downregulated, that initiates its own attenuation. 
Thrombomodulin is a transmembrane protein that is present on the undamaged 
endothelium, in particular the endothelium of the smaller blood vessels. The membrane-
bound thrombomodulin is able to capture thrombin by binding to the exosite I of thrombin 
upon which the thrombin-thrombomodulin complex is formed. The exosite I of thrombin is 
primarily involved in procoagulant interactions of the enzyme, namely in the recognition 
and activation of fibrinogen, FV and FVIII (Lane & Caso, 1989). After binding of 
thrombomodulin to the thrombin exosite I the procoagulant properties of any thrombin 
molecules that have migrated from a site of ongoing coagulation and are transported into 
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the microvasculature, are lost, thereby thrombomodulin is anticoagulant in itself. However, 
not only are the procoagulant properties of thrombin inhibited, given the fact that the active 
site of thrombin is still available, a conformational change that is accompanied by the 
binding to thrombomodulin causes the local active site structure of thrombin to change. This 
structural change alters the substrate specificity of thrombin (Fuentes-Prior et al, 2000; 
Dahlbäck & Villoutreix, 2005) such that thrombin is transformed from a procoagulant into 
an anticoagulant protein. In the anticoagulant state, thrombin is able to efficiently activate 
protein C by removal of a 12 amino acid activation fragment from the serine protease 
domain of protein C. For optimal activation of protein C by thrombin furthermore the 
presence of the endothelial cell protein C receptor (EPCR) is required.  
 
 
Fig. 1. Activation of protein C by thrombin. When bound to thrombomodulin (TM), in the 
presence of the endothelial cell protein C receptor (EPCR), thrombin (IIa) is able to activate 
protein C (PC) to activated protein C (APC). 
The physiological requirement for the presence of both thrombomodulin and EPCR is most 
strikingly evidenced by the early embryonic lethal phenotypes being associated with 
deficiency of either of the two proteins in mice (Fukudome & Esmon, 1994; Esmon, 2001). 
In the protein C pathway, a number of factors are important for the full expression of APC 
anticoagulant properties. These include the presence of the cofactor proteins, protein S and 
coagulation factor V (FV) and in addition a suitable membrane surface onto which both APC 
and its substrates can assemble in the presence of calcium.  
Like protein C, protein S is also a vitamin K dependent coagulation factor, which however is 
devoid of enzymatic activity as it does not contain a catalytic domain. FV, the procofactor 
protein, has a dual function in coagulation and has been described as a “Janus faced” 
protein (Nicolaes & Dahlbäck, 2002), with properties in both the pro- and anticoagulant 
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pathways. In the APC-catalyzed inactivation of FVIIIa (see also below) FV acts in synergy 
with protein S as a cofactor to APC (Shen & Dahlbäck, 1994; Varadi et al, 1995). Somewhat 
conflicting results were obtained whether or not FV is also a cofactor in the inactivation of 
FVa. Though extremely difficult to study in purified reaction systems, this issue was 
recently addressed (Cramer et al, 2010) and it was concluded that FV expresses activity in 
FVa inactivation. 
 
 
Fig. 2. APC catalyzed inactivation of FVa and FVIIIa. Left: APC, together with its cofactor 
protein S (PS) proteolytically inactivates factor Va (FVa) resulting in a loss of protein 
integrity and concomitant loss of cofactor activity. As a result, complex formation between 
FVa and factor Xa (FXa) is not possible, leading to lowered conversion of prothrombin by 
FXa. Right: analogous to regulation of FVa activity, factor VIIIa (FVIIIa) is leaved by APC, 
resulting in dissociation of FVIIIa units and loss of activity. Factor V, FV. Factor IXa, FIXa. 
In the absence of protein C, individuals are at high risk for the development of thrombosis, 
such as in the case of the classical homozygous protein C deficiencies that are seen in 
neonates where purpura fulminans develop (Dreyfus et al, 1991, 1995). This indicates the 
important function that the protein C pathway has, in particular in the microcirculation. Not 
only the deficiencies of the zymogen protein C, also those of the cofactor protein S are 
associated with a prothrombotic state. Deficiency of the other APC cofactor, FV, is by itself 
not associated with thrombosis, which indicates that, particularly at low FV levels, the 
procoagulant properties of this coagulation protein are dominant (Govers-Riemslag et al, 
2002; Duckers et al, 2009). There are however reports in literature in which cases were 
described where individuals who developed autoantibodies against FV have suffered from 
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thrombosis rather than from bleeding problems (Ortel, 1999). It was hypothesized that in 
these cases antibodies may specifically target the anticoagulant properties of FV. 
3. Structure and function of coagulations factors V and VIII  
FV and FVIII are large plasma glycoproteins, primarily synthesized in hepatocytes, with 
relative molecular masses of ~330 kDa that share a common architecture. Both proteins have 
a mosaic domain structure of A1-A2-B-A3-C1-C2 (Fig. 3). FV and FVIII share a common 
ancestral gene and are consequently structurally related, with 40% amino acid sequence 
identity in their A and C domains. The B-domain that connects the A1-A2 heavy chains and 
the A3-C1-C2 light chains are much less (~15%) conserved. Both FV and FVIII are heavily 
glycosylated, and the presence of the glycans is required for a proper folding and 
functioning of the cofactor proteins (Nicolaes et al, 1999; Yamazaki et al, 2010). 
The activated forms of FV and FVIII, called FVa and FVIIIa respectively, are required for full 
expression of activity by the prothrombinase and intrinsic tenase complexes respectively. In 
fact, FVa and FVIIIa are essential non-enzymatic cofactors: in the absence of the cofactors the 
prothrombinase and tenase complex are virtually inactive. 
To protect FVIII and to prevent premature expression of its cofactor activity, FVIII circulates 
in plasma in complex with von Willebrand factor (VWF), whereas FV in plasma is in free 
form (Weiss, 1977). In thrombocytes however, FV is bound to multimerin 1 (MMRN1), a 
large protein much like VWF, that protects FV from expression of its activity and 
presumably from intracellular degradation (Hayward, 1995). Upon activation of FV, the 
binding affinity of multimerin for FVa is decreased slightly, which will allow dissociation of 
the multimerin-FVa complex (Jeimy, 2008).  A similar mechanism, modification of affinity 
by activation, has also been described for the binding between FVIII and VWF (Lollar, 1988). 
The circulating procofactors FV and FVIII possess negligible activity and for them to gain 
activity, they need to be proteolyzed. During activation, the large B-domain will be excised 
from the molecule. In fact it has been shown for FV that the presence of the B-domain itself 
is the reason that the cofactor is not active and that proteolysis is needed to eliminate steric 
and/or conformational restraints that are imposed on the cofactor by the B-domain. A lifting 
of these restraints by removal of the B-domain allows the availability of discrete binding 
interactions between FVa and its binding partners FXa and prothrombin (Kane, 1990; Keller 
1995; Toso, 2004). Activation of FV and FVIII is essentially a positive feedback reaction since 
the potential activators are alpha-thrombin (Kane et al, 1981; Suzuki et al, 1982), 
meizothrombin (Tans et al, 1994), FXa (Monkovic & Tracy, 1990), FXIa (Whelihan et al, 2010) 
and tissue factor-FVIIa (Safa et al, 1999). Of these, activation by alpha-thrombin, the very 
enzyme that is produced by the prothrombinase complex, is regarded as most important. 
The cleavages by thrombin and FXa are indicated in Fig 3. For both cofactors these result in 
the release of the B-domain, a process that is accompanied by expression of cofactor activity. 
The molecular weight of the FVa light chain is not unique due to incomplete N-
glycosylation at Asn2181 in the C2 domain (Nicolaes et al, 1999; Kim et al, 1999). As a result 
of this variable glycosylation, two different forms of FV are present in human blood. These 
two glycoisoforms express different activities in both pro- and anticoagulation pathways 
(Váradi et al 1996, Hoekema et al, 1997) and glycosylation of the FVa light chain, more 
precisely the N-linked glycosylation at Asn2181, has been implicated in the pathogenesis of 
venous thrombosis (Yamazaki et al, 2002, 2010). 
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Fig. 3. Activation of FV and FVIII. The domain structures of FV (top) and FVIII (bottom) are 
indicated. FV is activated by thrombin or FXa at Arg709, Arg1018, and Arg1545, as indicated 
by the black arrows. The active cofactor is formed by the association of the A1-A2 heavy 
chain with the A3-C1-C2 light chain via calcium-dependent noncovalent bonding. FVIII is 
cleaved at residues Arg1313 and Arg1648 (upper arrows in purple) upon secretion from the 
cell, yielding a 200-kDa fragment (also referred to as the heavy chain, consisting of the A1, 
A2 and part of the B-domain) and an 80-kDa light chain. FVIII thus circulates as a dimer. 
Activation of FVIII by thrombin or FXa occurs through proteolytic cleavage at Arg372, 
Arg740, and Arg1689 (black arrows), yielding the heterotrimeric FVIIIa, consisting of a 50-
kDa A1 domain–derived polypeptide, a 43-kDa A2 domain–derived polypeptide, and the 
73-kDa A3-C1-C2–derived light chain, which are noncovalently associated via divalent 
metal ions. 
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The function of the cofactors FVa and FVIIIa is, like their structure, very similar. Both 
proteins express their cofactor activities when assembled in a membrane-bound complex 
that furthermore comprises a serine protease (FXa and FIXa respectively) and a zymogen-
substrate (prothrombin and FX respectively). A functional complex is only formed in the 
presence of calcium. Calcium is needed for the Gla-domains of the vitamin K dependent 
proteins involved to reach their calcium-induced active conformation (Huang et al, 2004) 
and furthermore for the occupation of the single calcium binding sites in FVa and FVIIIa, 
which are necessary for expression of cofactor activity. 
Involvement of the cofactor protein Va and VIIIa increases the Vmax of the prothrombinase 
and tenase complex respectively, by several orders of magnitude. This implies that the 
presence of FVa or FVIIIa is essential for the formation of thrombin or FXa under 
physiological conditions (Nesheim et al, 1979; Rosing et al, 1980, van Diejjen, 1981).  
4. Regulation of FVa and FVIIIa activities 
Given their potency and essential character, it is of prime importance for homeostasis that 
the activities of FVa and FVIIIa are tightly regulated. As mentioned above, the main 
proteolytic process responsible for FVa/FVIIIa regulation is limited proteolysis by the serine 
protease activated protein C (APC).  
The inactivation process occurs much in analogy to the activation described before: APC 
targets its substrates at multiple but specific cleavage sites, provided that both the substrate 
and the enzyme are bound to a membrane surface (Kalafatis et al, 1994; Nicolaes et al, 1995, 
Egan et al, 1997, Barhoover & Kalafatis, 2011). In the absence of a lipid surface, reactions 
occur too slowly to be physiologically relevant (Bakker et al., 1992; Nicolaes et al, 1995). 
Cleavage at each of the cleavage sites is characterized by its own kinetic parameters and 
since there is no specific order of cleavages, the rates of the cleavage reactions are being 
determined mostly by the local concentrations of FVa, APC and any cofactors or modifiers 
present. Though cleavages are random, the reaction products formed after cleavage at each 
of the single cleavage sites express different residual cofactor activities. For FVa this means 
that where cleavage at Arg306 results in a complete loss of protein integrity, cleavage at 
Arg506 results in a reaction product that has considerable remaining cofactor activity, an 
activity which will depend on the concentrations of other reactants present (e.g. FXa, 
Nicolaes et al., 1995). 
At a concentration around or lower than the plasma concentration of FV (21 nM) the 
cleavage at Arg506 is the preferred cleavage however, being ~20 fold faster than cleavage at 
Arg306. The inactivation of FVa is enhanced by the presence of protein S which selectively 
appears to stimulate the slower cleavage at Arg306 by a factor of 20 (Walker, 1981; Rosing et 
al, 1995), the dominant cleavage at Arg506 is only stimulated 2-fold by protein S (Rosing et 
al, 1995; Norstrom et al, 2006). Interesting to note in this respect is a recent finding that 
protein S, which circulates in both a free form and in complex with C4b binding protein 
(C4BP) has different effects on APC- catalyzed FVa inactivation, depending on whether it is 
free or not. Whereas it had prior been deemed that only free protein S is active as a cofactor 
to APC, it was shown that also the protein S-C4BP complex is able to stimulate the Arg306 
cleavage in FVa more than 10-fold, while cleavage at Arg506 is inhibited 3- to 4-fold 
(Maurissen et al, 2008). In the absence of protein S, FVa when incorporated in the 
prothrombinase complex, is protected from inactivation by APC. FXa specifically protects 
FVa from cleavage at Arg506 (Rosing et al, 1995; Norstrom et al, 2006), whereas 
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prothrombin has no preferred protection and attenuates the cleavage at both Arg306 and 
Arg506 (Rosing et al, 1995; Smirnov et al, 1999; Tran et al, 2008). 
 
 
Fig. 4. APC-catalyzed inactivation of FVa and FVIIIa. FVa Inactivation proceeds primarily 
via cleavages after residues Arg306 and Arg506 and to a lesser extent at Arg679 in the heavy 
chain domain (Kalafatis et al, 1994; Nicolaes et al, 1995) (upper grey arrows). In FVIIIa, APC 
targets the peptides bonds after Arg336 and Arg562(Fay et al, 1991), (upper grey arrows). 
For FVa, cleavage at Arg506 is preferred over that at Arg306. Full loss of activity requires 
cleavage at Arg306. Complete cleavage by APC then results in a loss of protein integrity, 
generating inactivated FVa, FVi, and inactivated FVIIIa, FVIIIi. The disintegration is 
accompanied by a loss of protein activity. Cofactors that influence the reactions are 
indicated: protein S and FV are able to enhance the cleavages in both FVa and FVIIIa, 
whereas FXa and prothrombin (PT) are able to protect FVa from inactivation by APC. 
Likewise, FIXa and FX are protective for FVIIIa.  
A quantitative explanation for the protection by FXa has recently been given, since both 
APC and FXa bind with similar affinity to similar/overlapping binding regions on the 
surface of FVa and thus are in direct competition for complex formation with FVa (Nicolaes 
et al, 2010). Interesting in this respect is the observation that APC, when bound to FVa can 
completely but reversibly inhibit the activity of FVa, even in the absence of irreversible 
cleavage of FVa by APC (Nicolaes et al, 2010). 
APC-mediated cleavages in FVIIIa occur at Arg336-Met337 and Arg562-Gly563 (Fay et al, 
1991) and are, like is the case for FVa, not ordered but rather determined by kinetic 
parameters and local concentrations of FVIIIa, APC and other proteins that may modify the 
reaction kinetics  (Fig. 4, upper grey arrows). This means that Arg336 is usually cleaved first 
and, very similar to FVa, a secondary cleavage at Arg562 is required for a complete loss of 
activity (Varfaj et al, 2006; Gale et al., 2008). The relevance of APC-catalyzed inactivation of 
FVIIIa is not undisputed since, in contrast to FVa, FVIIIa is not stable and its activity is 
subject to rapid decay caused by dissociation of the A2 domain from the rest of the 
molecule. Note that FVIIIa is a heterotrimer, with the A1 domain being separated from the 
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A2 domain. It has been estimated that the majority of FVIIIa activity (70-80%) is lost 
spontaneously (Lollar et al, 1990).  
Moreover, the affinity of APC for FVIIIa was estimated to be ~100-fold lower than the 
affinity of APC for FVa (Nicolaes et al, 2010), which may indicate the lesser importance of 
APC-catalyzed FVIIIa inactivation, especially if the 100-fold lower plasma concentration of 
FVIII, as compared to FV, is taken into account. When FVIIIa is incorporated in the tenase 
complex however, FVIIIa is much more stable and a role for FVIIIa regulation by APC 
becomes more evident. Like is the case for FVa, when incorporated in the prothrombinase 
complex, FVIIIa is protected from APC-catalyzed inactivation not only by increased stability 
of the FVIIIa heavy chain, FIXa and FX have been reported to selectively protect FVIIIa from 
cleavage at Arg336 and Arg562 (O’Brien et al, 2000). 
APC-catalyzed FVIIIa inactivation is specifically enhanced by the synergistic cofactors 
protein S and FV. In FVIIIa, cleavage at Arg562 is most pronouncedly enhanced in the 
presence of protein S, though FV and protein S stimulate both APC cleavage sites in FVIIIa 
(Shen & Dahlbäck, 1994; Varadi et al, 1996; Lu et al, 1996; Gale et al, 2008).  Resultingly, 
when both protein S and FV are present, cleavage at Arg336 and Arg562 occurs at similar 
rates in FVIIIa (Gale et al., 2008). 
5. APC resistance: First observations 
In 1993, a first report (Dahlbäck et al, 1993) was published in which three different families 
were described that presented an abnormal anticoagulant response to APC when the plasma 
of family members was tested in a  classical activated partial thromboplastin time (APTT) . 
In the plasma of normal individuals a prolongation of the APTT will occur when APC is 
added. However, for certain family members of the families studied, this prolongation was 
observed to be much less than for other family members or normal controls. The plasmas 
showed a poor response to APC and the term “APC resistance” was coined.  APC resistance 
was found to be an inheritable trait that was hypothesized to be caused by a defective 
function of a hitherto unknown cofactor to APC (Dahlbäck & Hildebrand, 1994).  A 
surprisingly large proportion of thrombophilic patients, vz. 20-60%, proofed to be resistant 
to APC and thus the new discovery attracted broad scientific interest (Griffin et al, 1993; 
Koster et al, 1993; Svensson & Dahlbäck, 1994; Halbmayer et al, 1994). 
To discover a molecular mechanism for APC resistance, attempts were made to isolate the 
unknown cofactor from normal plasma and this revealed that this factor was FV (Dahlbäck 
& Hildebrand, 1994). Addition of FV to an APC resistant plasma sample could normalize 
the response to APC. This was the first evidence that FV is not only a procoagulant protein, 
but these experiments established FV as well as an anticoagulant protein. Soon after, the 
involvement of the FV gene was confirmed. In 1994 several research groups succeeded 
simultaneously in the identification of the molecular cause for APC resistance by a thorough 
study of the FV gene of APC resistant individuals. The cause was identified as a single 
nucleotide polymorphism (SNP) at position 1691 which codes for a missense mutation at 
Arg506, replacing the arginine by glutamine, exactly at one of the APC cleavage sites in FVa. 
The FV gene containing the Arg506 mutation was since then described as FVLeiden, 
FVR506Q or FV:Q506. (Bertina et al, 1994; Zöller et al, 1994; Voorberg et al, 1994; Greengard 
et al, 1994). 
With a genetic cause unveiled and relatively easy DNA sequencing technologies becoming 
increasingly available, the allelic frequencies of the FVLeiden mutation was studied in 
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various patient and ethnic populations. The FVLeiden mutation was found in ~95% of 
families with APC resistance, which makes FVLeiden the major cause of hereditary APC 
resistance (Zöller et al, 1994). The FVLeiden mutation is very common in general 
populations though it is found exclusively in populations of Caucasian descent (~5% of 
Europeans are carrier of the mutation) and the high prevalence implied that, at the time, 
inherited APC resistance was 10 times more prevalent than the sum of all other hereditary 
causes of thrombophilia known (Rees et al, 1995, 1996). The FVLeiden mutation is known as 
the most common hereditary causal factor for thrombosis, by virtue of the APC resistance it 
causes in its carriers. 
6. The molecular basis of FVLeiden related APC resistance 
The role that the FVLeiden mutation, i.e. the replacement of arginine by a glutamine at 
position 506, has in the etiology of APC resistance been well studied. Several mechanisms 
contribute to the explanation of the prothrombotic tendency that is present in carriers of the 
mutation. First, given that the mutation abrogates the preferred mutation at Arg506, this 
means that one of the prime APC cleavage sites is lost in FVaLeiden. The absence of a 
cleavage site will impair efficient downregulation of procoagulant FVa activity (Kalafatis et 
al, 1994, Nicolaes et al, 1995). Second, it was discovered that for FV to act as a cofactor in the 
APC-catalyzed inactivation of FVIIIa, it must not be cleaved by thrombin (more precisely, 
the C-terminal region of the B domain must be intact) and furthermore, FV should be 
cleavable at Arg506 (Thorelli et al, 1998, 1999). This implies that FVLeiden, is not a cofactor 
in the inactivation of FVIIIa by APC, since it cannot be transformed into an anticoagulant 
molecule (Varadi et al, 1996).  Third, it was found that APC also possesses a proteolysis-
independent anticoagulant activity (Gale et al, 1997; Nicolaes et al, 2010). By virtue of its 
binding to FVa, thereby effectively competing with FXa for prothrombinase complex 
formation, APC is able to down-regulate thrombin formation in the absence of FVa cleavage. 
It was estimated that the non-enzymatic anticoagulant effect accounts for ~6% of the overall 
APC activity. In the case of FVaLeiden however, APC is not able to bind to the FVa region 
around the most favored cleavage site at Arg506 and consequently APC cannot regulate the 
activity of FVaLeiden via the proteolysis-independent mechanism. 
Taken together, the FVLeiden mutation has an effect both on the inactivation of FVa and of 
FVIIIa, the two cofactors that are essential to thrombin formation, and the inactivation of 
which was shown to be both contributing to APC resistance in the plasma of FVLeiden 
carriers (Castoldi et al, 2004). 
The in vivo effects of FVLeiden are perhaps most strikingly illustrated in the APC resistance 
phenotype that is observed in the plasma of so-called pseudo-homozygous APC resistant 
individuals. The individuals are genotyped as heterozygous FVLeiden carriers. However, 
their phenotype is that of a homozygous FVLeiden carrier. Due to a null-mutation in their 
normal FV allele, the normal FV is lacking in these individuals and only the FVLeiden allele 
is expressed (at ~50% of a normal FV level). The associated thrombosis risk in pseudo-
homozygotes is in the same range as that of homozygous carriers of the FVLeiden mutation 
(50- to 80-fold increased). When purified FV is however added to pseudohomozygous 
plasma, the response to APC is corrected such that it will reach the same range as that of 
heterozygous carriers of the FVLeiden mutation. Heterozygous carriers however have an 
associated risk of thrombosis that is ~5-fold higher than normals. The increased risk of 
thrombosis in homozygous and pseudohomozygous carriers of the FVLeiden mutation 
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therefore appears not so much to be caused by a defect in the FVLeiden that is present, more 
likely it illustrates the absence of the anticoagulant normal FV (Simioni et al, 1996, 2005; 
Castoldi et al., 2004; Brugge et al, 2005). 
7. Modifiers of the APC resistance phenotype  
The discovery of the FVLeiden mutation boosted the research into APC resistance and APC 
resistance as such was established as an indepent risk factor for thrombosis (de Visser et al, 
1999) even when the FVLeiden mutation was not present. Research showed that in 10-15% 
of individuals who are APC resistant (as determined via an APTT-based assay), the 
FVLeiden mutation is not present (Taralunga et al, 2004; Tosetto et al, 2004). This implies 
that besides FVLeiden, other factors exist that may modify the outcome of an APC resistance 
assay. These modifying factors of the APC resistance phenotype can be roughly divided into 
genetic and acquired factors and of the genetic factors, those that originate from the FV gene 
have been best studied. 
Important to mention is the fact that, since APC resistance is diagnosed according to the 
function of APC in plasma, the very test that is used to determine the presence of APC 
resistance is of influence as to whether a certain individual is described as APC resistant or 
normal. This is illustrated by the observation that in the endogenous thrombin potential 
(ETP) -based APC resistance assay (Nicolaes et al, 1997), most of the non-FVLeiden APC 
resistant samples are caused by an abnormal female hormonal status (as in pregnancy, 
hormone replacement therapy or oral contraceptive (OC) use) (Rosing et al, 1997;  Curvers et 
al, 2002). In the APTT-based APC resistance assays other factors besides OC use and 
pregnancy were found to be prevalent among cases on non-FVLeiden APC resistance. These 
include high FVIII levels, elevated prothrombin levels, malignancy and the presence of 
lupus anticoagulants (Henkens et al, 1995; Cumming et al, 1995; Laffan & Manning, 1996; 
Aznar et al, 1997; Tosetto et al, 1997; de Visser et al, 1999; Castaman et al, 2001; Tosetto et al, 
2004; Taralunga et al, 2004; Sarig et al, 2005). 
Several allelic variants of the FV gene have been described that contribute to the APC 
resistance phenotype and to venous thrombosis. FV Cambridge (Williamson et al, 1998) and 
FV Hong Kong (Chan et al, 1998) were both discovered in thrombosis patients. One of the 
predominant APC cleavage sites, at Arg306, is replaced in both these FV variants as a result 
of a missense mutation in the FV gene. In FV Cambridge Arg306 is replaced by Thr, and in 
FV Hong Kong Arg306 is replaced by a Gly residue. Interestingly, whereas FV Cambridge 
was discovered in the plasma of an individual with unexplained APC resistance, FV Hong 
Kong was not associated with APC resistance. This phenotypic difference has thus far not 
been explained. Investigations with recombinant FV variants that mimic FV Hong Kong and 
FV Cambridge have shown that both recombinant FV variants have only a slightly 
decreased APC response in a plasma system with an in vitro APC resistance phenotype 
being intermediate between those of normal FV and FVLeiden (Norstrom et al, 2002). 
Epidemiological studies have shown that FV Hong Kong is not a risk factor for venous 
thrombosis whereas more data on the rare FV Cambridge condition are needed to establish 
whether or not this FV genotype is associated with venous thrombosis. 
The FV2 haplotype is characterized by several linked mutations (both missense and silent) 
in exons 4,8,13, 16, and 25 of the gene for FV associated with slightly reduced FV levels. It 
has a high incidence in the general population (10-15%) (Bernardi et al, 1997; de Visser et al, 
2000). Especially when present in combination with FVLeiden, R2 FV may enhance the APC 
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resistance phenotype (the majority of circulating FV will be FVLeiden) and increase the risk 
of thrombosis (Faioni et al, 1999) Moreover, carriers of the R2 allele seem to have increased 
amounts of FV1 in their plasma (Castoldi et al, 2000; Hoekema et al, 2001). FV1 is a 
glycosylation isoform of FV that may be more thrombogenic than the other isoform, FV2 
(Hoekema et al, 1997). Where the reduced FV levels in R2 FV carriers can be attributed to the 
Asp2194Gly mutation (Yamazaki et al, 2002, 2010) it remains questionable whether the R2 
FV molecule itself is APC resistant. 
Another FV-related cause for APC resistance is the so-called FVLiverpool. In this variant, 
which was found in two related individuals with severe thrombosis at a young age, Ile359 
has been replaced by Thr (Mumford et al, 2003; Steen et al, 2004). This missense mutation 
introduces a novel site for N-linked glycosylation at Asn357. Due to the presence of an extra 
glycan structure, APC-catalyzed inactivation at Arg306 is hampered by steric hindrance. 
Like in the case of FVLeiden, FVLiverpool is not active as a cofactor to APC in the APC-
catalyzed inactivation of FVIIIa such that the mutation affects both inactivation of FVa and 
FVIIIa. 
Besides these mentioned mutated FV variants, also autoantibodies have been reported to be 
associated with APC resistance. In three cases, these antibodies were directed against FV 
(Ortel, 1999), however also antibodies against protein S (Nojima et al, 2009) and APC  
(Zivelin et al, 1999) have been described in this context. An exact causal mechanism for the 
thrombosis in these cases is not known, but may involve the broader context of an anti-
phospholipid syndrome. In addition, the coverage of epitopes on the surface of FV, that are 
in particular important for the FV anticoagulant functions, have been suggested. 
Given that APC resistance is diagnosed from plasma samples and knowing that human 
plasma contains many proteins that contribute to the functional assay outcome, it will be 
conceivable that APC resistance as such cannot be attributable to a single cause. Whether or 
not acquired factors such as pregnancy, malignancy, oral contraceptives or hormone 
replacement are involved, a final outcome of the interaction of genetic and acquired factors 
is the potential change of several important coagulation factors. A change in the level of 
these coagulation factors, and in particular, prothrombin, protein S, FVIII or tissue factor 
pathway inhibitor (TFPI) may influence assay outcome and render a plasma sample APC 
resistant (de Visser et al, 2005). 
8. Genetic and acquired interactions determine thrombosis risks 
Given that thrombosis is a multi-factorial disease, several factors can work in concert so as 
to disturb the haemostatic balance (Seligsohn & Zivelin, 1997; Rosendaal, 1999). Whether or 
not the presence of APC resistance, with its high prevalence in the general population, will 
result in a thrombosis, is dependent on the interplay between the various factors that 
influence the haemostatic balance in an individual (Martinelli, 2001). The contribution of 
inherited risk factors to the total risk for thrombosis development was estimated over 60%, 
and of these, the FVleiden mutation is considered the most important by virtue of its very 
high prevalence. 
Risk factors may show synergism in the events that cause a thromboembolic episode as was 
concluded from several studies where it was found that the prevalence of the FVLeiden 
mutation was much higher in thrombotic families with antithrombin, protein C or protein S 
deficiencies or with the HR2 haplotype or the prothrombin G20210A mutation, than in the 
general population. Not only is the prevalence of the FVLeiden mutation higher than 
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expected, also the combined risks for thrombosis in these families are much higher than 
what would be concluded from the sum of the risks associated with the single 
thrombophilic defects present (Koeleman et al, 1995; Gandrille et al, 1995; van Boven et al, 
1999; Faioni et al, 1999; Salomon et al, 1999). 
Not only gene-gene, also gene-environment (which is interpreted as interactions between a 
genetically determined risk factor and an acquired risk factor) contribute significantly to the 
overall risk for thrombosis. This type of interaction includes interactions between FVLeiden 
and the antiphospholipid syndrome (Simantov et al, 1996), or those between FVLeiden and 
long-distance travel or immobilization (Cannegieter et al, 2006; Schreijer et al, 2010).  
 
group 
FVLeiden                       OC use 
Risk* RR 
  
no no 0.8 1.0 
no yes 3.0 3.7 
yes no 5.7 6.9 
yes yes 28.5 34.7 
*Indicated are annual thrombosis risks (Risk) per 10,000 individuals and the related relative risk (RR) 
the data were obtained from Vandenbroucke et al, 1994 
Table 1. Interaction between carriership of the FVLeiden mutation and OC use 
The most studied interaction however, in this respect, is that between carriership of the 
FVLeiden mutation and the use of oral contraceptives (OC) (Vandenbroucke et al, 1994, 
2001; Wu et al, 2005; van Hylckama Vlieg, 2009). Given the world-wide use of OC, this is an 
interaction of great importance. As is illustrated by Table 1, the relative risk for thrombosis 
is ~ 5 fold higher in FVLeiden carriers who use OC than in those who do not use OC. 
Interaction between the risk factors, both having effects on the protein C anticoagulant 
system, is the likely cause for the overall multiplicative risk which is higher than the sum of 
the individual risks. This is illustrated by the various changes in coagulation parameters that 
have been associated to the use of OC or pregnancy: lowering of protein S, rise in 
prothrombin levels, lowering of FV levels, rise in FVIII levels, a rise in the levels of FIX and 
FX and a decrease in the TFPI levels. Each of these changes can have an effect on the 
coagulability of the blood (Tchaikovsky & Rosing, 2010), which overall changes the APC 
resistance phenotype. 
9. Conclusion 
The protein C pathway is vital for a normal haemostatic balance in that it down-regulates 
thrombin formation by inactivation of the non-enzymatic cofactor molecules of the 
prothrombinase en tenase complex. Resistance to APC, or “APC resistance”, is a functional 
defect of the protein C anticoagulant pathway, characterized by a reduced responsiveness of 
plasma to the addition of APC. Several factors, both genetic or acquired, can act in concert 
and result in an APC resistant phenotype. In a great majority of cases, the presence of the 
FVLeiden, a widespread hereditary variation of the gene product of FV, is involved. 
FVLeiden contributes to APC resistance in multiple ways, affecting both the inactivation of 
FVa and of FVIIIa. Given its high penetrance in the general population, the simultaneous 
occurrence of FVLeiden and other risk factors for thrombosis is common. Knowledge about 
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the interactions between various risk factors and the underlying mechanisms that result in 
the onset of thrombosis is vital to our understanding, diagnosis and treatment of 
thrombosis. 
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Thrombophilia(s) is a condition of increased tendency to form blood clots. This condition may be inherited or
acquired, and this is why the term is often used in plural. People who have thrombophilia are at greater risk of
having thromboembolic complications, such as deep venous thrombosis, pulmonary embolism or
cardiovascular complications, like stroke or myocardial infarction, nevertheless those complications are rare
and it is possible that those individuals will never encounter clotting problems in their whole life. The enhanced
blood coagulability is exacerbated under conditions of prolonged immobility, surgical interventions and most of
all during pregnancy and puerperium, and the use of estrogen contraception. This is the reason why many
obstetricians-gynecologysts became involved in this field aside the hematologists: women are more frequently
at risk. The availability of new lab tests for hereditary thrombophilia(s) has opened a new era with reflections
on epidemiology, primary healthcare, prevention and prophylaxis, so that thrombophilia is one of the hottest
topics in contemporary medicine.
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